Table 2.
Demographics of 976 healthcare workers sampled February 2023.
| 1-4 prior infections (N=877) |
No prior infection (N=99) |
Overall (N=976) |
|
|---|---|---|---|
| Age | |||
| Median [Min, Max] |
52 [24, 78] | 56 [24, 75] | 53 [24, 78] |
| Sex | |||
| Female | 763 (87.0%) | 90 (90.9%) | 853 (87.4%) |
| Male | 114 (13.0%) | 9 (9.1%) | 123 (12.6%) |
| Vaccine doses | |||
| No Vaccine | 24 (2.7%) | 0 (0%) | 24 (2.5%) |
| One dose | 8 (0.9%) | 1 (1.0%) | 9 (0.9%) |
| Two doses | 62 (7.1%) | 4 (4.0%) | 66 (6.8%) |
| Three doses | 403 (46.0%) | 43 (43.4%) | 446 (45.7%) |
| Four doses | 333 (38.0%) | 45 (45.5%) | 378 (38.7%) |
| Five doses | 47 (5.3%) | 6 (6.1%) | 53 (5.4%) |
| Primary vaccination | |||
| Adenoviral vector* + mRNA** |
185 (21.1%) | 25 (25.3%) | 210 (21.5%) |
| Adenoviral vector* x 1 |
1 (0.1%) | 0 (0%) | 1 (0.1%) |
| Adenoviral vector* x 2 |
95 (10.8%) | 13 (13.1%) | 108 (11.1%) |
| mRNA** x 1 | 7 (0.8%) | 1 (1.0%) | 8 (0.8%) |
| mRNA** x 2 | 565 (64.5%) | 60 (60.6%) | 625 (64.0%) |
| No vaccine | 24 (2.7%) | 0 (0%) | 24 (2.5%) |
| Vaccine dose 3 | |||
| mRNA bivalent*** |
2 (0.2%) | 0 (0%) | 2 (0.2%) |
| mRNA** | 781 (89.1%) | 94 (94.9%) | 875 (89.7%) |
| No third dose | 94 (10.7%) | 5 (5.1%) | 99 (10.1%) |
| Vaccine dose 4 | |||
| mRNA bivalent*** |
187 (21.3%) | 26 (26.2%) | 213 (21.8%) |
| mRNA** | 193 (22.0%) | 25 (25.3%) | 218 (22.4%) |
| No fourth dose |
497 (56.7%) | 48 (48.5%) | 545 (55.8%) |
| Vaccine dose 5 | |||
| mRNA bivalent*** |
38 (4.4%) | 4 (4.0%) | 42 (4.3%) |
| mRNA** | 9 (1.0%) | 2 (2.0%) | 11 (1.1%) |
| No fifth dose |
830 (94.6%) | 93 (94.0%) | 923 (94.6%) |
| Time since infection (days) | |||
| Median [Min, Max] |
371 [14, 1050] | NA | 371 [14, 1050] |
| Missing**** | 73 (8.3%) | 99 (100%) | 172 (17.6%) |
*ChadOx nCoV-19 **mRNA-1273 or BNT162b2 ***mRNA-1273.214, BNT162B2 Bivalent or mRNA-1273.222 (WT/BA.4-5 or WT/BA.1) ****73 individuals were assessed or previously infected based on IgG Nucleocapsid seroconversion.NA, Not Applicable.